pancreatic ductal adenocarcinoma
Conditions
Brief summary
EFS, defined as the time from randomization to: RECIST 1.1 progression [At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study
Detailed description
OS, RECIST 1.1 response rate, CA19.9 response rate, complete pathologic response, resectability rate, surgical mortality and morbidity rate, intra- and post-operative metastasis rate, N0 and R0 resections rate, patients reported outcomes, treatment toxicity
Interventions
DRUGAbraxane 5 mg/ml powder for dispersion for infusion.
DRUGcomprimé pelliculé
DRUGsolution à diluer pour perfusion
DRUGOxaliplatino Aurovit 5 mg/ml concentrado para solución para perfusión EFG
DRUGFluorouracil/Anabiosis 50 mg/ml διάλυμα για ένεση ή έγχυση
Sponsors
Associazione Italiana Per Lo Studio Del Pancreas
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EFS, defined as the time from randomization to: RECIST 1.1 progression [At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study | — |
Secondary
| Measure | Time frame |
|---|---|
| OS, RECIST 1.1 response rate, CA19.9 response rate, complete pathologic response, resectability rate, surgical mortality and morbidity rate, intra- and post-operative metastasis rate, N0 and R0 resections rate, patients reported outcomes, treatment toxicity | — |
Countries
Italy
Outcome results
None listed